Chromosome 22q11.2 deletion syndrome: Difference between revisions
Jump to navigation
Jump to search
imported>Daniel Mietchen m (Velocardiofacial syndrome moved to Chromosome 22q11.2 deletion syndrome: alternative name) |
imported>Daniel Mietchen (slight addition) |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Chromosome 22q11.2 deletion syndrome''' (also known as velocardiofacial syndrome or DiGeorge syndrome) is a clinical condition due to [[microdeletion]]s in the [[chromosome band|11.2 region]] on [[human chromosome 22]]. It was first diagnosed in 1968 as an [[immunological]] syndrome but has since been found to be associated with a wide [[phenotype|phenotypic]] spectrum which also includes [[cardiovascular]], [[craniofacial]] and [[brain morphometric]] abnormalities as well as [[cognitive impairment]]s. It affects about one in 5000 newborn children and can be diagnosed with a [[genetic test]]. | '''Chromosome 22q11.2 deletion syndrome''' (also known as velocardiofacial syndrome or DiGeorge syndrome) is a clinical condition due to [[microdeletion]]s in the [[chromosome band|11.2 region]] on [[human chromosome 22]]. It was first diagnosed in 1968 by [[Angelo DiGeorge]] as an [[immunological]] syndrome but has since been found to be associated with a wide [[phenotype|phenotypic]] spectrum which also includes [[cardiovascular]], [[craniofacial]] and [[brain morphometric]] abnormalities as well as [[cognitive impairment]]s. It affects about one in 5000 newborn children and can be diagnosed with a [[genetic test]]. | ||
Revision as of 04:51, 25 November 2009
Chromosome 22q11.2 deletion syndrome (also known as velocardiofacial syndrome or DiGeorge syndrome) is a clinical condition due to microdeletions in the 11.2 region on human chromosome 22. It was first diagnosed in 1968 by Angelo DiGeorge as an immunological syndrome but has since been found to be associated with a wide phenotypic spectrum which also includes cardiovascular, craniofacial and brain morphometric abnormalities as well as cognitive impairments. It affects about one in 5000 newborn children and can be diagnosed with a genetic test.